# COVID SARS-CoV-2 Assessment Viral Evolution (SAVE) VARIANT TESTING

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2021 · $6,477,336

## Abstract

COVID SARS-CoV-2 Assessment Viral Evolution (SAVE) variant testing provides support for analysis of SARS-CoV-2 genome sequences from specimens collected in COVID-19 therapeutic and observational trials for genetic variants that could impact diagnostics, therapeutics, vaccine efficacy, and disease severity. COVID SAVE provides support for the analysis of the impact of SARS-CoV-2 variants on disease severity in animal models and in vitro neutralization assays. Additionally, COVID SAVE variant testing allows analysis of the evolution of SARS-CoV-2 and identification of future variants with potential public health impacts.

## Key facts

- **NIH application ID:** 10505861
- **Project number:** 75N91019D00024-P00005-759102000004-2
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** SALIBA KATY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $6,477,336
- **Award type:** —
- **Project period:** 2020-08-31 → 2022-08-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10505861

## Citation

> US National Institutes of Health, RePORTER application 10505861, COVID SARS-CoV-2 Assessment Viral Evolution (SAVE) VARIANT TESTING (75N91019D00024-P00005-759102000004-2). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10505861. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*